Posts By: pharmanewsdaily

Nano Pulse Stimulation, bioelectric stimulation can treat skin lesions

According to a new study published in the special issue of the journal Bioelectricity, most of the human diseases including skin lesions can be treated by applying bioelectrical impulses. The Nano-Pulse Stimulation (NPS) technique works by delivering nanosecond pulsed electric fields to cells and tissues. NPS specifically targets cells to generate nanometer wide pores and […]

TenNor Therapeutics gets FDA orphan drug status for TNP-2092 in prosthetic joint infections

TenNor Therapeutics has secured orphan drug designation from the US Food and Drug Administration (FDA) for its multitargeting drug conjugate TNP-2092 for the treatment of prosthetic joint infections. According to the Chinese biopharma company, biofilm infections associated with prosthetic joints, central venous catheters, artificial heart valves, and other medical devices has become a huge challenge. […]

BioTheryX begins BTX-A51 phase 1 trial in AML and myelodysplastic syndrome

BTX-A51 phase 1 trial : US biotech company BioTheryX has initiated patient dosing in its first clinical program of its small molecule BTX-A51 in patients having relapsed/refractory acute myeloid leukemia (AML), and also in high-risk myelodysplastic syndrome patients. The phase 1 clinical trial of BTX-A51 will assess the safety, pharmacokinetics, and tolerability of the oral […]

Frazier Healthcare Partners raises $617m for life sciences fund

Frazier Healthcare Partners has closed its third life sciences fund – Frazier Life Sciences X, at more than $617 million in capital commitments. The Seattle-based private equity and venture capital firm has been investing in life sciences since more than 29 years ago Since its inception, Frazier Healthcare Partners has raised its total committed capital to approximately $4.8 […]

Arena Pharmaceuticals’ APD418 gets FDA fast track status in decompensated heart failure

Arena Pharmaceuticals has secured that fast track designation for its drug candidate APD418 from the US Food and Drug Administration (FDA) for the treatment of decompensated heart failure (DHF). APD418 is a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope. According to the San Diego-based biopharma company, APD418 is a selective antagonist that has been designed […]

Cerevel launches phase 3 Parkinson’s disease clinical trials for tavapadon

Parkinson’s disease clinical trials : Cerevel Therapeutics, a US biopharma company, has initiated a phase 3 clinical trial program for evaluating tavapadon in Parkinson’s disease patients, as per the latest clinical trial news. Tavapadon is being developed as an orally-bioavailable, selective partial agonist of the dopamine D1 and D5 receptors, and is being assessed for […]

Scroll To Top